Insulin/insulin suspension isophane biosimilar - Wockhardt

Drug Profile

Insulin/insulin suspension isophane biosimilar - Wockhardt

Alternative Names: Biphasic insulin isophane biosimilar - Wockhardt; Consegna 30/70; Insulin suspension isophane/insulin biosimilar - Wockhardt; Recombinant (r-DNA) human insulin biphasic - Wockhardt; Wosulin 30/70; Wosulin 50/50

Latest Information Update: 10 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Wockhardt
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Type 1 diabetes mellitus

Most Recent Events

  • 02 Oct 2017 Wockhardt initiates a phase I BA/BE trial in healthy volunteers in India (SC) (CTRI/2017/08/009251)
  • 03 Aug 2017 Wockhardt plans a phase I BA/BE trial in healthy volunteers in India (SC) (CTRI/2017/08/009251)
  • 21 Aug 2013 Wockhardt terminates a phase III trial in Type 1 diabetes mellitus in USA and India (NCT01308437)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top